At MD Anderson, we work under the same roof as world-class physicians and researchers, providing unparalleled insights that guide each of our programs. We learn from those we treat, starting with a patient and their cancer in order to drive new therapeutics based on specific unmet needs.
To discover and develop effective new therapies, we have created state-of-the-art research platforms with industry-scale capabilities and collaborative teams of experts driven toward a singular goal: improving the lives of our patients.
Therapeutics Discovery Research Platforms
Discovering therapies to treat neurological disorders and cancer-related cognitive conditions
Impactful cell therapies
The Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., was launched to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. CTMC is built upon the Biologics Development platform, formerly part of Therapeutics Discovery.Learn more about CTMC
Our collaborative agreements with leading pharmaceutical and biotechnology companies also are critical to our mission of advancing impactful therapies. These agreements can take a variety of forms based on how best to meet the needs of our patients.
By aligning with leading biopharmaceutical companies and strategic investors, we are able to combine the unique infrastructure and drug development capabilities of Therapeutics Discovery with the novel therapeutics and expertise of our collaborators to accelerate new therapies to benefit patients.
Establishing new companies allows us to advance promising medicines discovered and developed by our teams with the managerial, operational and investment expertise of our strategic partners.
We have licensed novel therapeutics discovered within our platforms to companies committed to advancing these medicines toward patients in need, often collaborating for ongoing development and early-stage clinical trials.